Clinical Trial

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-24.
Status change: Not Yet Recruiting → Recruiting 2026-01-08
Trial Details
NCT Number NCT07268040
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Malignant Solid Tumors
Enrollment 400 participants
Start Date 2025-12-23
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-12